195
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

The Add-Arm Design for Unimodal Response Curve with Unknown Mode

&
Pages 1039-1064 | Received 23 Feb 2013, Accepted 10 Aug 2014, Published online: 07 Jul 2015

References

  • Armitage, P. (1955). Tests for linear trends in proportions and frequencies. Biometrics (International Biometric Society) 11(3):375–386.
  • Baker, W. F., Jr. (2000). Iron deficiency in pregnancy, obstetrics, and gynecology. Hematology/Oncology Clinics of North America 14:1061–1077.
  • Bauer, P., Koenig, F., Brannatha, W., Poscha, M. (2010). Selection and bias—Two hostile brothers. Statistics in Medicine 29:1–13.
  • Berry, D. A., Muller, P., Grieve, A. P., Smith, M., Parke, T., Blazek, R., Mitchard, N., Krams, M. (2001). Adaptive Bayesian designs for dose-ranging drug trials. In Case Studies in Bayesian Statistics V. New York, NY: Springer-Verlag. pp. 99–181.
  • Bowden, J., Glimm, E. (2008). Unbiased estimation of selected treatment means in two-stage trials. Biometrical Journal 50(4):515–527.
  • Brannath, W., Koenig, F., Bauer, P. (2006). Estimation in flexible two stage designs. Statistics in Medicine 25:3366–3381.
  • Bretz, F., Pinheiro, J. C., Branson, M. (2005). Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 61:738–748.
  • Carreras, M., Brannath, W. (2012). Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection. Statistics in Medicine. doi:10.1002/sim.5463.
  • Chang, M. (2012). Adaptive design and simulation. In Deming Conference 2012, NJ, USA. December 2012.
  • Chang, M. (2007). Adaptive Design Theory and Implementation using SAS and R. Boca Raton, FL: CRC.
  • Cochran, W. G. (1954). Some methods for strengthening the common Chi-squared tests. Biometrics (International Biometric Society) 10(4):417–451.
  • Dragalin, V., Fedorov, V. (2006). Adaptive designs for dose-finding based on efficacy–toxicity response. Journal of Statistical Planning and Inference 136:1800–1823.
  • Dragalin, V., Fedorov, V., Wu, Y. (2008). Adaptive designs for selecting drug combinations based on efficacy–toxicity response. Journal of Statistical Planning and Inference 138:352–373.
  • Dunnett, C. W. (1955). A multiple comparison procedure for comparing several treatments with a control. Journal of the American Statistical Association 50:1096–1121.
  • Dunnett, C. W. (1964). New tables for multiple comparisons with a control Biometrics 20:482–491.
  • Heritier, S., Lô, S. N., Morgan, C. C. (2011). An adaptive confirmatory trial with interim treatment selection: practical experiences and unbalanced randomization. Statistics in Medicine 30:1541–1554.
  • Huang, W. S., Liu, J. P., Hsiao, C. F. (2011). An alternative Phase II/III design for continuous endpoints. Pharmaceutical Statistics 10:105–114.
  • Ivanova, A., Liu, K., Snyder, E., Snavely, D. (2009). An adaptive design for identifying the dose with the best efficacy/tolerability profile with application to a crossover dose finding study. Statistics in Medicine 28:2941–2951.
  • Ivanova, A., Xiao, C., Tymofyeyev, Y. (2012). Two-stage designs for Phase 2 dose-finding trials. Statistics in Medicine 31:2872–2881.
  • Jenkins, M., Stone, A., Jennison, C. (2011). An adaptive seamless Phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Pharmaceutical Statistics 10:347–356.
  • Johnson, N., Kotz, S., Balakrishnan, N. (1994). Continuous Univariate Distributions, Vol. 1, 2nd ed. New York, NY: Wiley Interscience, John-Wiley & Sons.
  • Kathman, S. J., Hale, M. D. (2007). Combining estimates from multiple early studies to obtain estimates of response: using shrinkage estimates to obtain estimates of response. Pharmaceutical Statistics 6: 297–306.
  • Looker, A. C., Dallman, P. R., Carroll, M. D., Gunter, E. W., Johnson, C. L. (1997). Prevalence of iron deficiency in the United States. JAMA 277:973–976.
  • Maca, J., Bhattacharya, S., Dragalin, V., Gallo, P., Krams, M. (2006). Adaptive seamless Phase II/III designs-Background, operational aspects, and examples. Drug Information Journal 2:463–473.
  • Miller, F., Guilbaud, O., Dette, H. (2007). Optimal designs for estimating the interesting part of a dose-effect curve. Journal of Biopharmaceutical Statistics 17:1097–1115.
  • Nam, J. (1987). A simple approximation for calculating sample sizes for detecting linear trend in proportions. Biometrics 43(3):701–705.
  • Posch, M., Maurer, M., Bretz, F. (2011). Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim. Pharmaceutical Statistics 10:96–104.
  • Stallard, N., Todd, S., Whitehead, J. (2008). Estimation following selection of the largest of two normal means. Journal of Statistical Planning and Inference 138:1629–1638.
  • Stallard, N., Todd, S. (2005). Point estimates and confidence regions for sequential trials involving selection. Journal of Statistical Planning and Inference 135:402–419.
  • Shun, Z., Lan, G., Soo, Y. (2008). Interim treatment selection using the normal approximation approach in clinical trials. Statistics in Medicine 27:597–618.
  • William, D.A. (1972). Comparison of several dose levels with a zero dose control. Biometrics 28:519–531.
  • Zwillinger, D., Kokoska, S. (2000). Standard Probability and Statistics Tables and Formulae. Boca Raton, FL: Chapman & Hall/CRC, pp. 61–62.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.